VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Garcia-Manero on Deferasirox in Iron Chelation Therapy for MDS

Guillermo Garcia-Manero, MD
Published: Thursday, May 07, 2015



Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the new formulation of deferasirox (Jadenu) as an iron chelation therapy for patients with myelodysplastic syndromes (MDS).

Garcia-Manero says the new formulation of deferasirox may allow iron chelation therapy to be significantly easier for patients to tolerate. Less toxicity may allow for greater access and use of the compound.

However, Garcia-Manero adds that the therapy may be expensive, and that there is a need for more data. Results are anticipated for the randomized TELESTO trial, which examined the use of deferasirox in patients with MDS.



Guillermo Garcia-Manero, MD, chief, Section of Myelodysplastic Syndromes, deputy chair, Translational Research, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the new formulation of deferasirox (Jadenu) as an iron chelation therapy for patients with myelodysplastic syndromes (MDS).

Garcia-Manero says the new formulation of deferasirox may allow iron chelation therapy to be significantly easier for patients to tolerate. Less toxicity may allow for greater access and use of the compound.

However, Garcia-Manero adds that the therapy may be expensive, and that there is a need for more data. Results are anticipated for the randomized TELESTO trial, which examined the use of deferasirox in patients with MDS.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x